Skip to main content
Top
Published in: Supportive Care in Cancer 12/2016

01-12-2016 | Original Article

Multidrug infusions in a Swiss palliative care unit: assessment of frequent combinations in terms of clinical effectiveness, compatibility, and stability

Authors: Tanja Fusi-Schmidhauser, Dario Caronzolo, Claudia Gamondi

Published in: Supportive Care in Cancer | Issue 12/2016

Login to get access

Abstract

Purpose

The objectives of this study were to trace, monitor, and assess for clinical effectiveness, visual compatibility, and stability of commonly used combinations of drugs for patients hospitalized in a Swiss palliative care unit, over a 12-month period.

Methods

In this longitudinal analysis, commonly used multidrug combinations were monitored with a duly created data collection sheet for healthcare professionals. Assessment of visual changes of the mixtures and the evaluation of major changes in the overall symptom control over time were recorded. The clinical changes were classified according to reasonable correlation to the modality of drug administration and not to clinical evolution of the underlying disease.

Results

Over a 12-month period, a total of 48 multidrug infusions were recorded and monitored. The infusions were composed of two, three, four, or five active principles. Infusions were given over a 24-h period, mainly intravenously, either through an implantable venous access port or a peripheral venous access. Main diluent was normal saline solution. Commonly used drug combinations included morphine and haloperidol, morphine, haloperidol and octreotide, morphine, haloperidol, octreotide, and chlorpromazine. No precipitations were observed during the study. Patients maintained a clinical stability and no salient changes in symptom control were attributed to inefficacy of the multidrug infusions.

Conclusions

The use of multidrug infusions for parenteral administration appears to confirm an adequate visual compatibility and stability, while maintaining effectiveness in terms of overall symptom control.
Literature
2.
go back to reference Potter J, Hami F, Bryan T, Quigley C (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17:310–314CrossRefPubMed Potter J, Hami F, Bryan T, Quigley C (2003) Symptoms in 400 patients referred to palliative care services: prevalence and patterns. Palliat Med 17:310–314CrossRefPubMed
3.
go back to reference Lidstone V, Butter E, Seed PT, Sinott C, Beynon T, Richards M (2003) Symptoms and concerns amongst cancer outpatients: identifying the need for specialist palliative care. Palliat Med 17:588–595CrossRefPubMed Lidstone V, Butter E, Seed PT, Sinott C, Beynon T, Richards M (2003) Symptoms and concerns amongst cancer outpatients: identifying the need for specialist palliative care. Palliat Med 17:588–595CrossRefPubMed
4.
go back to reference Nauck F, Alt-Epping B (2008) Crises in palliative care—a comprehensive approach. Lancet Oncol 9:1086–1091CrossRefPubMed Nauck F, Alt-Epping B (2008) Crises in palliative care—a comprehensive approach. Lancet Oncol 9:1086–1091CrossRefPubMed
5.
go back to reference Wilcock A, Jacob JK, Charlesworth S, Harris E, Gibbs M, Allsop H (2006) Drugs given by a syringe driver: a prospective multicenter survey of palliative care services in the UK. Palliat Med 20:661–664CrossRefPubMed Wilcock A, Jacob JK, Charlesworth S, Harris E, Gibbs M, Allsop H (2006) Drugs given by a syringe driver: a prospective multicenter survey of palliative care services in the UK. Palliat Med 20:661–664CrossRefPubMed
6.
go back to reference Hanks G, Cherny NI, Christakis NA, Fallon M, Kaasa S, Portenoy RK (2010) Oxford textbook of palliative medicine. Oxford University Press, Oxford Hanks G, Cherny NI, Christakis NA, Fallon M, Kaasa S, Portenoy RK (2010) Oxford textbook of palliative medicine. Oxford University Press, Oxford
9.
go back to reference Menahem S, Shvartzman P (2010) Continuous subcutaneous delivery of medications for home care palliative care patients—using an infusion set or a pump ? Support Care Cancer 18:1165–1170CrossRefPubMed Menahem S, Shvartzman P (2010) Continuous subcutaneous delivery of medications for home care palliative care patients—using an infusion set or a pump ? Support Care Cancer 18:1165–1170CrossRefPubMed
10.
go back to reference Herndon CM, Fike DS (2001) Continuous subcutaneous infusion practices of United States hospices. J Pain Symptom Manag 22:1027–1034CrossRef Herndon CM, Fike DS (2001) Continuous subcutaneous infusion practices of United States hospices. J Pain Symptom Manag 22:1027–1034CrossRef
11.
go back to reference Culshaw J, Kendall D, Wilcock A (2013) Off-label prescribing in palliative care: a survey of independent prescribers. Palliat Med 27:314–319CrossRefPubMed Culshaw J, Kendall D, Wilcock A (2013) Off-label prescribing in palliative care: a survey of independent prescribers. Palliat Med 27:314–319CrossRefPubMed
12.
go back to reference Verhagen CC, Niezink AG, Engels YY, Hekster YY, Doornebal JJ, Vissers KC (2008) Off-label use of drugs in pain medicine and palliative care: an algorithm for the assessment of its safe and legal prescription. Pain Practice 8:157–163CrossRefPubMed Verhagen CC, Niezink AG, Engels YY, Hekster YY, Doornebal JJ, Vissers KC (2008) Off-label use of drugs in pain medicine and palliative care: an algorithm for the assessment of its safe and legal prescription. Pain Practice 8:157–163CrossRefPubMed
13.
go back to reference Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermoken JB, Bruyneel P (1998) Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 23:311–314CrossRefPubMed Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermoken JB, Bruyneel P (1998) Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 23:311–314CrossRefPubMed
14.
go back to reference Bruera E, Brenneis C, Michaud M, Bacovsky R, Chadwick S, Emeno A, MacDonald N (1998) Use of the subcutaneous route for administration of narcotics in patients with cancer pain. Cancer 62:407–411CrossRef Bruera E, Brenneis C, Michaud M, Bacovsky R, Chadwick S, Emeno A, MacDonald N (1998) Use of the subcutaneous route for administration of narcotics in patients with cancer pain. Cancer 62:407–411CrossRef
15.
go back to reference Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E (2006) Morphine, haloperidol and hyoscine-N-butylbromide in s.c. infusion solutions: compatibility and stability. Evaluation in terminal oncology patients. Int J Pharm 307:278–284CrossRefPubMed Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E (2006) Morphine, haloperidol and hyoscine-N-butylbromide in s.c. infusion solutions: compatibility and stability. Evaluation in terminal oncology patients. Int J Pharm 307:278–284CrossRefPubMed
16.
go back to reference Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7:6–9PubMed
17.
go back to reference Twycross R, Wilcock A, Howard P (eds) (2014) Palliative care formulary. Palliativedrugs.com Ltd, Nottingham University Hospitals NHS Trust, Nottingham Twycross R, Wilcock A, Howard P (eds) (2014) Palliative care formulary. Palliativedrugs.com Ltd, Nottingham University Hospitals NHS Trust, Nottingham
18.
go back to reference Burridge N (ed) (2005) Australian injectable drugs handbook, 3rd edn. Society of Hospital Pharmacists of Australia, Collingwood Burridge N (ed) (2005) Australian injectable drugs handbook, 3rd edn. Society of Hospital Pharmacists of Australia, Collingwood
19.
go back to reference Vermeire A, Remon JP, Schrijvers D, Demeulenaere P (2002) A new method to obtain and present complete information on the compatibility: study of its validity for eight binary mixtures of morphine with drugs frequently used in palliative care. Palliat Med 16:417–424CrossRefPubMed Vermeire A, Remon JP, Schrijvers D, Demeulenaere P (2002) A new method to obtain and present complete information on the compatibility: study of its validity for eight binary mixtures of morphine with drugs frequently used in palliative care. Palliat Med 16:417–424CrossRefPubMed
20.
go back to reference Barcia E, Reyes R, Azuara ML, Sanchez Y, Negro S (2003) Compatibility of haloperidol and hyoscine-N-butylbromide in mixtures for subcutaneous infusion to cancer in palliative care. Support Care Cancer 11:107–103PubMed Barcia E, Reyes R, Azuara ML, Sanchez Y, Negro S (2003) Compatibility of haloperidol and hyoscine-N-butylbromide in mixtures for subcutaneous infusion to cancer in palliative care. Support Care Cancer 11:107–103PubMed
21.
go back to reference Mitten T (2001) Subcutaneous drug infusions: a review of problems and solutions. Int J Palliat Nurs 7:75–85CrossRefPubMed Mitten T (2001) Subcutaneous drug infusions: a review of problems and solutions. Int J Palliat Nurs 7:75–85CrossRefPubMed
22.
go back to reference Vainio A, Auvinen A for the Symptom Prevalence Group (1996) Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manag 12(1):3–10CrossRef Vainio A, Auvinen A for the Symptom Prevalence Group (1996) Prevalence of symptoms among patients with advanced cancer: an international collaborative study. J Pain Symptom Manag 12(1):3–10CrossRef
23.
go back to reference Fainsinger RL, Spachynski K, Hanson J, Bruera E (1994) Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manag 9:12–18CrossRef Fainsinger RL, Spachynski K, Hanson J, Bruera E (1994) Symptom control in terminally ill patients with malignant bowel obstruction. J Pain Symptom Manag 9:12–18CrossRef
24.
go back to reference Negro S, Azuara ML, Sanchez Y, Reyes R, Barcia E (2002) Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 10:65–70CrossRefPubMed Negro S, Azuara ML, Sanchez Y, Reyes R, Barcia E (2002) Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 10:65–70CrossRefPubMed
25.
go back to reference Destro M, Ottolini L, Vicentini L, Boschetti S (2012) Physical compatibility of binary and ternary mixtures of morphine and methadone with other drugs for parental administration in palliative care. Support Care Cancer 20:2501–2509CrossRefPubMed Destro M, Ottolini L, Vicentini L, Boschetti S (2012) Physical compatibility of binary and ternary mixtures of morphine and methadone with other drugs for parental administration in palliative care. Support Care Cancer 20:2501–2509CrossRefPubMed
26.
go back to reference Huang E, Anderson RP (1994) Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. Am J Hosp Pharm 51:2963PubMed Huang E, Anderson RP (1994) Compatibility of hydromorphone hydrochloride with haloperidol lactate and ketorolac tromethamine. Am J Hosp Pharm 51:2963PubMed
27.
go back to reference Knudsen L, Eisend S, Haake N, Kunze T (2014) Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine. Eur J Hosp Pharm 21:161–166CrossRef Knudsen L, Eisend S, Haake N, Kunze T (2014) Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine. Eur J Hosp Pharm 21:161–166CrossRef
28.
go back to reference Nasser S, Dubuc MC, Lavoie P, Brazier JL (2003) HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate, and scopolamine. J Liquid Chromatogr Relat Technol 26:2909–2929CrossRef Nasser S, Dubuc MC, Lavoie P, Brazier JL (2003) HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate, and scopolamine. J Liquid Chromatogr Relat Technol 26:2909–2929CrossRef
29.
go back to reference Ölçer M, Hakyemez G (1988) Investigations of some physicochemical properties of haloperidol which may affect its activity. J Clin Pharm Ther 13:341–349CrossRefPubMed Ölçer M, Hakyemez G (1988) Investigations of some physicochemical properties of haloperidol which may affect its activity. J Clin Pharm Ther 13:341–349CrossRefPubMed
30.
31.
go back to reference Morgan S, Evans N (2004) A small observational study of the longevity of syringe driver sites in palliative care. Int J Palliat Nurs 10:405–412CrossRefPubMed Morgan S, Evans N (2004) A small observational study of the longevity of syringe driver sites in palliative care. Int J Palliat Nurs 10:405–412CrossRefPubMed
Metadata
Title
Multidrug infusions in a Swiss palliative care unit: assessment of frequent combinations in terms of clinical effectiveness, compatibility, and stability
Authors
Tanja Fusi-Schmidhauser
Dario Caronzolo
Claudia Gamondi
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3357-1

Other articles of this Issue 12/2016

Supportive Care in Cancer 12/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine